Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells

European Journal of Cancer

Volumn 36, Issue 6, 2000, Pages 787-795

  Kirschke, H ^a,b   Eerola, R ^b   Hopsu Havu, V K ^b   Bromme D ^c   Vuorio, E ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF TURKU   (Finland)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense RNA; Cathepsin B; Cathepsin L; L cells; Myeloma SP cells; Procathepsin L; Tumour growth

Indexed keywords

CATHEPSIN B; CATHEPSIN L; COMPLEMENTARY DNA; COMPLEMENTARY RNA; LUCIFERASE; PROTEINASE;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL LINE; CONTROLLED STUDY; L CELL; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; BLOTTING, NORTHERN; CATALYSIS; CATHEPSIN B; CATHEPSINS; CELL DIVISION; CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; L CELLS (CELL LINE); MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RNA, ANTISENSE; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034075042     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00014-9     Document Type: Article

References (34)

1. Mignatti P., Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73:1993;161-195.
2. Danø K., Grøndahl-Hansen J., Eriksen J., Schnack Nielsen B., Rømer J., Pyke C. The receptor for urokinase plasminogen activator. stromal cell involvement in extracellular proteolysis during cancer invasion Portland Press Proc. 6:1993;239-245.
3. Newell K., McDonnell S., Witty J.P., Gaire M., Rodgers W.H., Matrisian L.M. The stromelysin subclass of metalloproteinases in tumour progression and metastasis. Portland Press Proc. 6:1993;253-261.
4. Rochefort H., Capony F. Alterations of cathepsin D in human breast cancer. Portland Press Proc. 6:1993;233-238.
5. Denhardt D.T., Greenberg A.H., Egan S.E., Hamilton R.T., Wright J.A. Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts. Oncogene. 2:1987;55-59.
6. Gottesman M.M. Cathepsin L and cancer. Portland Press Proc. 6:1993;247-251.
7. Kirschke H. Lysosomal cysteine peptidases and malignant tumours. Adv. Exp. Med. Biol. 421:1997;253-257.
8. Kobayashi H., Ohi H., Sugimura M., Shinohara H., Fujii T., Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res. 52:1992;3610-3614.
9. Yagel S., Warner A.H., Nellans H.N., Lala P.K., Waghorne C., Denhardt D.T. Suppression by cathepsin L inhibitors of the invasion of amnion membranes by murine cancer cells. Cancer Res. 49:1989;3553-3557.
10. Weber E., Günther D., Laube F., Wiederanders B., Kirschke H. Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for tumour growth. J. Cancer Res. Clin. Oncol. 120:1994;564-567.
11. Jean D., Bar-Eli M., Huang S.et al. A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res. 56:1996;254-258.
12. Khokha R., Waterhouse P., Yagel S.et al. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science. 243:1989;947-950.
13. Kook Y.H., Adamski J., Zelent A., Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 13:1994;3983-3991.
14. Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294-5299.
15. Portnoy D.A., Erickson A.H., Kochan J., Ravetch J.V., Unkeless J.C. Cloning and characterization of a mouse cysteine proteinase. J. Biol. Chem. 261:1986;14697-14703.
16. Barrett A.J., Kirschke H. Cathepsin B, cathepsin H, and cathepsin L. Meth. Enzymol. 80:1981;535-561.
17. Mason R.W., Gal S., Gottesman M.M. The identification of the major excreted protein (MEP) from a transformed mouse fibroblast cell line as a catalytically active precursor form of cathepsin L. Biochem. J. 248:1987;449-454.
18. Langner J., Ansorge S., Bohley P., Kirschke H., Hanson H. Intracellular protein breakdown. I. Activity determinations of endopeptidases using protein substrates. Acta. Biol. Med. Ger. 26:1971;935-951.
19. Söderström M., Salminen H., Glumoff V., Kirschke H., Aro H., Vuorio E. Cathepsin expression during skeletal development. Biochim. Biophys. Acta. 1446:1999;35-46.
20. Srivastava R.A.K., Schonfeld G. Use of riboprobes for northern blotting analysis. Biotechniques. 11:1991;584-586.
21. 2. Biochem. Biophys. Res. Commun. 101:1981;454-458.
22. Wang B., Shi G.P., Yao P.M., Li Z.Q., Chapman H.A., Brömme D. Human cathepsin F. Molecular cloning, functional expression, tissue localization, and enzymatic characterization. J. Biol. Chem. 273:1998;32000-32008.
23. Kitajima I., Shinohara T., Bilakovics J., Brown D.A., Xu X., Nerenberg M. Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-κB. Science. 258:1992;1792-1795.
24. Wagner R.W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 372:1994;333-335.
25. Wagner E.G.H., Brantl S. Kissing and RNA stability in antisense control of plasmid replication. Trends Biochem. Sci. 23:1998;451-454.
26. Moroni M.C., Willingham M.C., Beguinot L. EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J. Biol. Chem. 267:1992;2714-2722.
27. Frade R., Rodrigues-Lima F., Huang S., Xie K., Guillaume N., Bar-Eli M. Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res. 58:1998;2733-2736.
28. Haeckel C., Krueger S., Roessner A. Antisense inhibition of urokinase. effect on malignancy in a human osteosarcoma cell line Int. J. Cancer. 77:1998;153-160.
29. Hasegawa S., Koshikawa N., Momiyama N.et al. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int. J. Cancer. 76:1998;812-816.
30. Castagnino P., Soriano J.V., Montesano R., Bottaro D.P. Induction of tissue inhibitor of metalloproteinases-3 is a delayed early cellular response to hepatocyte growth factor. Oncogene. 17:1998;481-492.
31. Ellis L.M., Liu W., Wilson M. Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation. Surgery. 120:1996;871-878.
32. Kasid U., Pfeifer A., Brennan T.et al. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science. 243:1989;1354-1356.
33. Bresalier R.S., Mazurek N., Sternberg L.R.et al. Metastasis of human colon cancer is altered by modifying expression of the β-galactoside-binding protein galectin 3. Gastroenterology. 115:1998;287-296.
34. Adatia R., Albini A., Carlone S.et al. Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA. Ann. Oncol. 8:1997;1257-1261.